Which stories were most popular among the venous community in 2025? Read our round-up of the trending articles which appeared across Venous News this year.
1. First patient treated with InterVene’s Recana thrombectomy catheter system
InterVene announces that the first patient has been treated with its Recana thrombectomy catheter system for venous in-stent restenosis (ISR). The company shares in a press release that Recana is the first fully integrated mechanical thrombectomy system designed specifically to address the long-term complications of venous disease, including ISR and native vein obstructions. The case was performed at University Hospital Galway in Galway, Ireland, by interventional radiologist Gerry O’Sullivan.
2. Study highlights declining venous stent patency rates after one year
A systematic review and meta-analysis of over 1,500 venous stenting procedures—said to be the first study on this topic to date—has highlighted an 18% drop in primary patency rates after one-year follow-up with declining rates beyond 12 months. As a result, researchers highlight the need for surveillance and consideration of reintervention to optimise long-term outcomes.
3. Novel thrombectomy system for VTE used successfully in first tranche of first-in-human cases
SonoVascular announces the successful completion of an initial set of eight deep vein thrombosis (DVT) cases using its SonoThrombectomy system as part of a first-in-human (FIH) study of the device.
4. US FDA deems Envveno’s VenoValve “not-approvable”
The US Food and Drug Administration (FDA) has issued a letter to Envveno Medical stating that its VenoValve technology is “not-approvable,” a company press release published today reports. The letter was issued in response to Envveno’s premarket approval (PMA) application for VenoValve—a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
A large nationwide survey conducted by the Japanese Regulatory Committee for Endovascular Treatment of Varicose Veins has demonstrated that cyanoacrylate closure (CAC) for varicose veins is safe with low rates of serious adverse events, such as venous thromboembolism.
6. CX 2025: New VenaSeal data suggest cyanoacrylate closure be added to the venous “toolkit”
Twelve-month outcomes of the VenaSeal Spectrum venous leg ulcer (VLU) trial, assessing time to ulcer healing following treatment with the VenaSeal (Medtronic) closure system, have demonstrated an 81.3% ulcer healing rate at one year.
7. SCAI publishes chronic venous disease management guidelines
The Society for Cardiovascular Angiography & Interventions (SCAI) has released new, evidence-based clinical practice guidelines to support the treatment of chronic venous disease (CVD).
8. The evolving role of vascular surgery in the treatment of severe chronic venous insufficiency
Raghu Motaganahalli (Indiana University School of Medicine, Indianapollis, USA) discusses the expanding space of surgical treatment of severe chronic venous insufficiency (CVI), novel technologies that have emerged to address challenges and the data which may direct a pathway to best patient care.
9. Basis Medical announces successful first-in-human procedures using Seclusion catheter
Basis Medical has announced the successful completion of its first-in-human clinical procedures using the Seclusion catheter to treat chronic venous insufficiency (CVI) caused by superficial vein reflux. The cases were performed by Marcos Fletcher (Ciudad de Salud Hospital, Panama City, Panama).
10. Artificial intelligence tool predicts DVT risk following endovenous thermal ablation
A recent research article has detailed an artificial intelligence (AI) model that enables physicians to predict which patients with superficial venous insufficiency have a higher risk of developing deep vein thrombosis (DVT) following endovenous thermal ablation (EVTA).
